Page last updated: 2024-12-06

mepindolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mepindolol is a β-adrenergic receptor blocking agent, specifically a non-selective antagonist of both β1 and β2 receptors. It was synthesized in the 1970s and initially investigated for its potential use in treating hypertension and angina. Mepindolol's mechanism of action involves blocking the binding of norepinephrine and epinephrine to β-adrenergic receptors, thereby reducing heart rate and blood pressure. However, while mepindolol exhibited promising results in early studies, its clinical use has been limited due to its relatively short duration of action and potential side effects, including fatigue, dizziness, and bradycardia. Nonetheless, mepindolol continues to be studied for its potential applications in other areas, such as the treatment of glaucoma and the modulation of inflammation. It is also used as a research tool to investigate the role of β-adrenergic receptors in various biological processes.'

mepindolol: 2-methyl deriv of pindolol; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71698
CHEMBL ID65717
CHEBI ID135082
SCHEMBL ID79365
MeSH IDM0064522

Synonyms (37)

Synonym
1-(isopropylamino)-3-[(2-methylindol-4-yl)oxy]-2-propanol
mepindolol (inn)
D07181
23694-81-7
mepindolol
1-(isopropylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol
mepindololum [inn-latin]
einecs 245-831-1
CHEBI:135082
CHEMBL65717
L001371
1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol
rac mepindolol
1-[(1-methylethyl)amino]-3-[(2-methyl-1h-indol-4-yl)oxy]-2-propanol
unii-00q31er368
00q31er368 ,
mepindolol [inn:ban]
mepindololum
FT-0671018
mepindolol [inn]
mepindolol [mi]
mepindolol [who-dd]
SCHEMBL79365
1-(isopropylamino)-3-[(2-methyl-1h-indol-4-yl)oxy]-2-propanol #
corindolan (salt/mix)
NXWGWUVGUSFQJC-UHFFFAOYSA-N
2-propanol, 1-(isopropylamino)-3-[(2-methylindol-4-yl)oxy]-
2-propanol, 1-[(1-methylethyl)amino]-3-[(2-methyl-1h-indol-4-yl)oxy]-
mepicor (salt/mix)
betagon (salt/mix)
sh-e-222 (salt/mix)
AKOS027378779
Q2760233
DB13530
1-[(2-methyl-1h-indol-4-yl)oxy]-3-[(propan-2-yl)amino]propan-2-ol
DTXSID40865110
1-(isopropylamino)-3-((2-methyl-1h-indol-4-yl)oxy)propan-2-ol

Research Excerpts

Overview

Mepindolol is a newly developed beta-adrenergic blocking agent. It is reported to counteract the chronotropic effect of catecholamines, with only little effect on contractility.

ExcerptReferenceRelevance
"Mepindolol is a newly developed beta-adrenergic blocking agent reported to counteract the chronotropic effect of catecholamines, with only little effect on contractility. "( Mepindolol reduces myocardial necrosis in rats with coronary artery occlusion.
Ambrosio, G; Cappelli-Bigazzi, M; Chiariello, M; Condorelli, M; Marone, G; Perrone-Filardi, P; Tritto, I,
)
3.02
"Mepindolol is a newly developed beta-adrenergic blocking agent, which differs from other available beta-blockers in its ability to counteract the chronotropic effect of catecholamines without depressing myocardial contractility. "( [Mepindolol reduction of the degradation of phospholipids and the necrosis induced by myocardial ischemia].
Ambrosio, G; Cappelli Bigazzi, M; Chiariello, M; Pellegrino, A; Perrone Filardi, P; Vallone, C, 1985
)
2.62

Treatment

Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days. The drug was able to prevent ischemia-induced phospholipase activation.

ExcerptReferenceRelevance
"Mepindolol treatment decreased beta 2-adrenoceptor density from 1112.2 +/- 459.6 sites/cell to 295.1 +/- 131.2 sites/cell."( [Activity and number of lymphocyte beta adrenergic receptors after protracted treatment with mepindolol sulfate of patients with essential arterial hypertension].
Carretta, R; Castellano, M; De Biasi, F; Fabris, B; Fischetti, F; Leprini, R, 1990
)
1.22
"Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment."( Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".
Borchard, U; Brodde, OE; Daul, A; O'Hara, N; Stuka, N, 1985
)
0.99
"Mepindolol-treated rats, however, showed a phospholipid concentration of 0.70 +/- 0.04 microgram P/mg of protein (p less than 0.05), suggesting that the drug was able to prevent ischemia-induced phospholipase activation.(ABSTRACT TRUNCATED AT 250 WORDS)"( [Mepindolol reduction of the degradation of phospholipids and the necrosis induced by myocardial ischemia].
Ambrosio, G; Cappelli Bigazzi, M; Chiariello, M; Pellegrino, A; Perrone Filardi, P; Vallone, C, 1985
)
1.9

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic effects of acute and repeated application of a transdermal patch (BIO TSD) containing 20 mg of the beta-receptor blocking agent mepindolol were assessed in 13 normotensive male volunteers."( [Human pharmacologic studies on transdermal administration of mepindolol. Pharmacodynamic and orienting pharmacokinetics].
Chen, LS; Haase, W; Liedtke, RK; Mangold, B, 1989
)
0.72
" Synchronously with pharmacodynamics, pharmacokinetic data were also obtained after multiple dosing."( Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
Bonelli, J; Hitzenberger, G; Krause, W; Speck, U; Wendt, H, 1980
)
0.53
"6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet."( Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.
Krause, W; Lennert, C,
)
0.45

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of low doses was 1-2% in the rat and 40% in the dog."( Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences.
Krause, W; Kühne, G,
)
0.45
"The bioavailability and pharmacokinetics of 10 mg of mepindolol sulphate and of 25 mg of hydrochlorothiazide were compared in a cross-over design in five healthy volunteers after the administration of either the single drugs (Corindolan and Esidrix) or in combination (Tenesor)."( Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.
Krause, W; Lennert, C,
)
0.7

Dosage Studied

ExcerptRelevanceReference
" They were submitted to clinical exam, stress testing and plasma lipids dosage before and after four weeks of treatment."( [Effect of beta blockers with intrinsic sympathomimetic activity on blood pressure and blood lipids in patients with essential hypertension].
Bellotti, G; Braga, A; Pileggi, F; Santomauro, A; Serro-Azul, JB; Serro-Azul, LG; Wajngarten, M; Yazbek Júnior, P, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)35.87000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID41891Tested for intrinsic sympathomimetic activity (ISA); antagonist with partial agonistic properties1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID41488Selectivity for beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID40539Selectivity for beta-1 receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-199057 (82.61)18.7374
1990's11 (15.94)18.2507
2000's0 (0.00)29.6817
2010's1 (1.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.13 (24.57)
Research Supply Index4.60 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (32.43%)5.53%
Reviews2 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (64.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]